Diarylquinolines, synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207

Future Medicinal Chemistry

Volumn 3, Issue 11, 2011, Pages 1345-1360

  Guillemont, Jerome ^a   Meyer, Christophe ^a   Poncelet, Alain ^a   Bourdrez, Xavier ^a   Andries, Koen ^b  

^a Janssen Cilag Research Center   (France)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG SYNTHESIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTITUBERCULAR AGENTS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELA CELLS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES;

EID: 80052418174     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.79     Document Type: Article

References (32)

1. Chan ED, Iseman MD. Current medical treatment for tuberculosis. BMJ 325, 1282-1286 (2002). (Pubitemid 35430589)
2. Douglas JG, McLeod MJ. Pharmacokinetic factors in the modern treatment of tuberculosis. Clin. Pharmacokinet. 37(2), 127-146 (1999). (Pubitemid 29431480)
3. Floss HG, Yu TW. Rifamycin: mode of action, resistance, and biosynthesis. Chem. Rev. 105, 621-632 (2005). (Pubitemid 40351636)
4. Harries AD, Zachariah R, Corbett EL et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 375(9729), 1906-1919 (2010).
5. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375(9731), 2100-2109 (2010).
6. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 469, 483-490 (2011).
7. Guillemont J, Lieby-Muller F, Lounis N et al. New antituberculosis drugs in clinical development: an overview. Curr. Bioactive Compounds 5, 137-154 (2009).
8. Janin YL. Antituberculosis drugs: ten years of research. Bioorg. Med. Chem. 15, 2479-2513 (2007). (Pubitemid 46367698)
9. Ballel L, Field RA, Duncan K, Young RJ. New small-molecule synthetic antimicrobacterials. Antimicrob. Agents Chemother. 49, 2153-2163, (2005).
10. Andries, K, Verhasselt, P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223-227 (2005). (Pubitemid 40116230)
11. Koul, A. Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323-324 (2007). (Pubitemid 46789271)
12. Lougheed KEA, Taylor N et al. New anti-tuberculosis agents amongst known drugs. Tuberculosis 89(5), 364-370 (2009).
13. Handbook of anti-tuberculosis agents. Tuberculosis 88 (2), 85-169 (2008).
14. Jain R, Vaitilingam B, Nayyar A, Palde PB. Substituted 4-methylquinolines as a new class of anti-tuberculosis agents. Bioorg. Med. Chem. Lett. 13(16), 1051-1054 (2003). (Pubitemid 36331797)
15. Kunin CM, Ellis WY, Antimicrobial activities of mefloquine and a series of related compounds. Antimicrob. Agents Chemother. 44, 848-852 (2000). (Pubitemid 30165259)
16. Guillemont J. Diarylquinolines, a new class of anti-tuberculosis agents. Presented at: NITD TB Symposium. Cameroun, Africa, 10-15 October 2010
17. De Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K. A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 Proteins 67, 971-980 (2007). (Pubitemid 46753944)
18. Cramer RD, Patterson DE, Bunce JD, Comparative molecular field analysis (CoMFA).1 Effect of shape on binding of steroïds to carrier proteins. J. Am. Chem. Soc. 110(18), 5959-5967 (1988).
19. Cramer R.D. Topomer CoMFA: a design methodology for rapid lead optimization. J. Med. Chem. 46, 374-388 (2003). (Pubitemid 36139790)
20. Martin YC, Kim KH, Lin CT. Comparative molecular field analysis: CoMFA. In:Advances in Quantitative Structure-Property Relationships, Volume 1 Charton M. (Ed.).JAI Press Inc., Greenwich, CT, USA 1-52 (1996).
21. Gaurrand S, Desjardins S, Meyer C et al. Conformational analysis of R207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. J. Chem. Biol. Drug Des. 68, 77-84 (2006). (Pubitemid 44454425)
22. Petit S, Coquerel G, Meyer C, Guillemont J. Absolute configuration and structural features of R207910, a novel anti-tuberculosis agent. J. Mol. Struct. 837, 252-256 (2007). (Pubitemid 46590174)
23. Gaillard P, Carrupt PA, Testa B, Boudon A. Molecular lipophilicity potential, a tool in 3D QSAR: method and applications. J. Comput. Aided Mol. Des. 8(2), 83-96 (1994).
24. Carrupt PA, Gaillard P, Billois F et al. The molecular lipophilicity potential (MLP): a new tool for log P calculations and docking, and in comparative molecular field analysis (CoMFA).In: Lipophilicity in Drug Action and Toxicology. Pliska V, Testa B, van de Waterbeemd H (Eds).VCH Publishers, Weinheim, Germany 195-216 (1996).
25. Broto P, Moreau G, Vandicke C. Molecular structures: perception, autocorrelation descriptor and SAR studies. System of atomic contributions for the calculation of the n-octanol/water partition coefficients. Eur. J. Med. Chem. 19, 71-76 (1984).
26. Baurin N, Vangrevelinghe E, Morin-Allory L, Merour, JY et al. 3D-QSAR CoMFA study on imidazolinergic I2 ligands: a significant model through a combined exploration of structural diversity and methodology. J. Med. Chem. 43, 1109-1122 (2000). (Pubitemid 30173736)
27. Koul A, Vranckx L, Dendouga N et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273-25280 (2008).
28. Amacher D E. Drug-associated mitochondrial toxicity and its detection. Curr. Med. Chem. 12(16), 1829-1839 (2005). (Pubitemid 41015181)
29. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290-1292 (2009).
30. Lounis N, Veziris N, Chauffour A et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50(11), 3543-3547 (2006). (Pubitemid 44684863)
31. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360, 2397-2405 (2009).
32. Aksimentiev A, Balabin IA, Fillingame RH, Schulten K. Insights into the molecular mechanism of rotation in the F0 sector of ATP synthase. Biophys. J. 86, 1332-1344 (2004). (Pubitemid 38304846)